Belgium· BE-AMP-SAM665283-00

Yeytuo 300 mg

A lenacapavir product containing lenacapavir sodium, registered in Belgium by Gilead Sciences Ireland UC. The same ATC class is registered in 15 of our 19 countries.

ATC J05AX31

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedYeytuo 300 mgATCJ05AX31REGISTER NO.BE-AMP-SAM665283-00PACKS LISTED0CHECKEDSeptember 26, 2026

Where it is registered

Lenacapavir is registered in 15 of 19 countries.

Countries holding a registration under ATC J05AX31 (lenacapavir), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 10 of them publish a price we can compare per daily dose

Lenacapavir · ATC J05AX31

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lenacapavir costs, country by country.

Normalised to the WHO defined daily dose (0.19 g), the median price runs from $0.45 in France to $511.10 in Switzerland — a ×1140 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Lenacapavir · price per daily dose (0.19 g)

USD · FX 28 Sept 2026

  • CH Switzerland$511.10
  • FR France$0.45
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Lenacapavir Sodium
Manufacturer
Gilead Sciences Ireland UC
Country
Belgium (BE)
ATC code
J05AX31
ATC class
Lenacapavir
Defined daily dose
0.19 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Lenacapavir in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lenacapavir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Sunlenca, Yeytuo
  • Liechtenstein · Sunlenca, Yeytuo
  • Norway · Sunlenca, Yeytuo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d8d263e2-d6a2-40f4-a6eb-bb0f7e1042da
GET /v1/drugs/d8d263e2-d6a2-40f4-a6eb-bb0f7e1042da?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Yeytuo 300 mg",
  "name_fr": "Yeytuo 300 mg",
  "name_nl": "Yeytuo 300 mg",
  "amp_code": "SAM665283-00",
  "strengths": [
    "300.0000",
    "300.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Lenacapavir Sodium",
    "Lenacapavir",
    "Mannitol"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Lenacapavir",
  "authorisation_numbers": [
    "EU/1/25/1976/001"
  ]
}

See everything about lenacapavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.